Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review of Drug Abuse, Misuse, and Related Laboratory Challenges

Author(s): Haniye Ranjkeshzadeh, Samaneh Sepahi, Hadi Zare-Zardini, Mohammad Ehsan Taghavizadeh Yazdi, Adel Ghorani-Azam* and Abbas Jafari*

Volume 19, Issue 4, 2024

Published on: 08 November, 2023

Page: [417 - 430] Pages: 14

DOI: 10.2174/0115748863266621231023112044

Price: $65

Abstract

Various definitions can be considered for drugs and substance abuse. According to the National Institute on Abuse, the use of an over-the-counter drug in a different way than that prescribed to experience or arouse emotion is a simple form of drug abuse. The World Health Organization (WHO) also defines drug abuse as the persistent or sporadic use of drugs that are incompatible or unrelated to acceptable medical practice. With the increasing non-therapeutic use of prescription drugs, serious related consequences have also increased. Therefore, there is a need to know more precisely about the types of substances and drug abuse, which is the most important part of diagnosis and recognizing the tests that cause false positive and negative results. The purpose of this review article is to collect and summarize the most important and more common types of drugs of abuse and review the drugs that cause false results in screening tests. In addition, the most common detection methods of the drug will be reviewed and the advantages and drawbacks of each method will be discussed. In this article, we aimed to point out all the facts about the emerging problems in drug abuse, the methods of screening, and the possible false results in addition to troubleshooting strategies.

Keywords: Drug abuse, misuse, narcotics, screening tests, false positive results, false negative results.

« Previous Next »
Graphical Abstract

[1]
Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001; 2(2): 119-28.
[http://dx.doi.org/10.1038/35053570] [PMID: 11252991]
[2]
Goldstein RZ, Volkow ND. Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 2002; 159(10): 1642-52.
[http://dx.doi.org/10.1176/appi.ajp.159.10.1642] [PMID: 12359667]
[3]
Eddy NB, Halbach H, Isbell H, Seevers MH. Drug dependence: its significance and characteristics. Psychopharmacol Bull 1966; 3(3): 1-12.
[PMID: 5915847]
[4]
Westerhausen D, Perkins AJ, Conley J, Khan BA, Farber M. Burden of substance abuse-related admissions to the medical ICU. Chest 2020; 157(1): 61-6.
[http://dx.doi.org/10.1016/j.chest.2019.08.2180] [PMID: 31494083]
[5]
Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb Mortal Wkly Rep 2016; 65(5051): 1445-52.
[http://dx.doi.org/10.15585/mmwr.mm655051e1] [PMID: 28033313]
[6]
Baldwin WA, Rosenfeld BA, Breslow MJ, Buchman TG, Deutschman CS, Moore RD. Substance abuse-related admissions to adult intensive care. Chest 1993; 103(1): 21-5.
[http://dx.doi.org/10.1378/chest.103.1.21] [PMID: 8417881]
[7]
Balogun A, Esimai O, Olupeju A, Akinsulore A, Adagbasa E, Afolabi T. Prevalence of psychoactive substances use and quality of life of adolescents in secondary schools in Akoko North East Local Government Area Ondo State. J Med Surg Sci 2020; 2(1): 1-8.
[8]
Ugbedeojo Atumeyi A, Terungwa Ligom T, Terfa Tivkaa J. Intake and abuse of psychoactive substances and its relative consequences: A review. Sci J Analyt Chem 2021; 9(2): 39.
[http://dx.doi.org/10.11648/j.sjac.20210902.12]
[9]
Su S, Fairley CK, Mao L, et al. Estimates of the national trend of drugs use during 2000–2030 in China: A population-based mathematical model. Addict Behav 2019; 93: 65-71.
[http://dx.doi.org/10.1016/j.addbeh.2019.01.022] [PMID: 30685570]
[10]
Sugihartati R, Susilo D. Acts against drugs and narcotics abuse: Measurement of the effectiveness campaign on Indonesian narcotics regulator Instagram. J Stud Alcohol Drugs 2019; 8: 1-4.
[11]
Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open 2018; 1(2): e180217.
[http://dx.doi.org/10.1001/jamanetworkopen.2018.0217] [PMID: 30646062]
[12]
(a) Ignaszewski MJ. The epidemiology of drug abuse. J Clin Pharmacol 2021; 61(S2) (Suppl. 2): S10-7.
[http://dx.doi.org/10.1002/jcph.1937] [PMID: 34396554];
(b) Zaami S, Marinelli E, Varì MR. New trends of substance abuse during COVID-19 pandemic: an international perspective. Front Psychiatry 2020; 11: 700.
[http://dx.doi.org/10.3389/fpsyt.2020.00700] [PMID: 32765328]
[13]
Bewley-Taylor DR. Emerging policy contradictions between the United Nations drug control system and the core values of the United Nations. Int J Drug Policy 2005; 16(6): 423-31.
[http://dx.doi.org/10.1016/j.drugpo.2005.06.007]
[14]
Hill SL, Thomas SHL. Clinical toxicology of newer recreational drugs. Clin Toxicol (Phila) 2011; 49(8): 705-19.
[http://dx.doi.org/10.3109/15563650.2011.615318] [PMID: 21970769]
[15]
Fox T P, Oliver G, Ellis S M. The destructive capacity of drug abuse: An overview exploring the harmful potential of drug abuse both to the individual and to society. Int Sch Res Notices 2013; 2013
[16]
Riahi-Zanjani B, Balali-Mood M, Asoodeh A, Es’haghi Z, Ghorani-Azam A. Potential application of amino acids in analytical toxicology. Talanta 2019; 197: 168-74.
[http://dx.doi.org/10.1016/j.talanta.2019.01.019] [PMID: 30771919]
[17]
Ghorani-Azam A, Balali-Mood M, Khatami SM, Asoodeh A, Es’haghi Z, Riahi-Zanjani B. Plant extract and herbal products as potential source of sorbent for analytical purpose: an experimental study of morphine and codeine determination using HPLC and LC–MSMS. J Chromatogr Sci 2021; 59(5): 482-9.
[http://dx.doi.org/10.1093/chromsci/bmaa108] [PMID: 33388745]
[18]
Degenhardt L, Charlson F, Ferrari A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Psychiatry 2018; 5(12): 987-1012.
[http://dx.doi.org/10.1016/S2215-0366(18)30337-7] [PMID: 30392731]
[19]
Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. JAMA 2018; 319(17): 1819-21.
[http://dx.doi.org/10.1001/jama.2018.2844] [PMID: 29715347]
[20]
Vedotin B. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases 2012.
[21]
Volkow N, Benveniste H, McLellan AT. Use and misuse of opioids in chronic pain. Annu Rev Med 2018; 69(1): 451-65.
[http://dx.doi.org/10.1146/annurev-med-011817-044739] [PMID: 29029586]
[22]
Uddin MS, Sufian MA, Kabir MT, et al. Amphetamines: Potent recreational drug of abuse. J Addict Res Ther 2017; 8(4): 1-12.
[http://dx.doi.org/10.4172/2155-6105.1000330]
[23]
Winkelman TNA, Admon LK, Jennings L, Shippee ND, Richardson CR, Bart G. Evaluation of amphetamine-related hospitalizations and associated clinical outcomes and costs in the United States. JAMA Netw Open 2018; 1(6): e183758-8.
[http://dx.doi.org/10.1001/jamanetworkopen.2018.3758] [PMID: 30646256]
[24]
Silberman E, Balon R, Starcevic V, et al. Benzodiazepines: it’s time to return to the evidence. Br J Psychiatry 2021; 218(3): 125-7.
[http://dx.doi.org/10.1192/bjp.2020.164] [PMID: 33040746]
[25]
Cloos JM, Lim Cow CYS, Bocquet V. Benzodiazepine high‐doses: The need for an accurate definition. Int J Methods Psychiatr Res 2021; 30(4): e1888.
[http://dx.doi.org/10.1002/mpr.1888] [PMID: 34331787]
[26]
Zamboni L, Lugoboni F, Zandonai T. Benzodiazepine abuse among athletes: Pain relief or just a weapon against insomnia? A clinical case study. Scand J Med Sci Sports 2019; 29(12): 1937-40.
[http://dx.doi.org/10.1111/sms.13540] [PMID: 31419319]
[27]
Gunja N. The clinical and forensic toxicology of Z-drugs. J Med Toxicol 2013; 9(2): 155-62.
[http://dx.doi.org/10.1007/s13181-013-0292-0] [PMID: 23404347]
[28]
Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev 2018; 70(2): 197-245.
[http://dx.doi.org/10.1124/pr.117.014381] [PMID: 29487083]
[29]
Hong KB, Han SH, Park Y, Suh HJ, Choi HS. Romaine lettuce/skullcap mixture improves sleep behavior in vertebrate models. Biol Pharm Bull 2018; 41(8): 1269-76.
[http://dx.doi.org/10.1248/bpb.b18-00267] [PMID: 30068876]
[30]
Zammit G. Comparative tolerability of newer agents for insomnia. Drug Saf 2009; 32(9): 735-48.
[http://dx.doi.org/10.2165/11312920-000000000-00000] [PMID: 19670914]
[31]
Ebert B, Wafford KA, Deacon S. Treating insomnia: Current and investigational pharmacological approaches. Pharmacol Ther 2006; 112(3): 612-29.
[http://dx.doi.org/10.1016/j.pharmthera.2005.04.014] [PMID: 16876255]
[32]
Ayonrinde O, Sampson E. Physical dependence on zopiclone. Risk of dependence may be greater in those with dependent personalities. BMJ 1998; 317(7151): 146-6.
[PMID: 9696615]
[33]
Victorri-Vigneau C, Gérardin M, Rousselet M, Guerlais M, Grall-Bronnec M, Jolliet P. An update on zolpidem abuse and dependence. J Addict Dis 2014; 33(1): 15-23.
[http://dx.doi.org/10.1080/10550887.2014.882725] [PMID: 24467433]
[34]
Schifano F, Chiappini S, Corkery J, Guirguis A. Abuse of prescription drugs in the context of novel psychoactive substances (NPS): a systematic review. Brain Sci 2018; 8(4): 73.
[http://dx.doi.org/10.3390/brainsci8040073] [PMID: 29690558]
[35]
Lugoboni F, Mirijello A, Morbioli L, et al. Zolpidem high-dose abuse: what about the liver? Results from a series of 107 patients. Expert Opin Drug Saf 2019; 18(8): 753-8.
[http://dx.doi.org/10.1080/14740338.2019.1628216] [PMID: 31177863]
[36]
Schifano F, Chiappini S, Corkery JM, Guirguis A. An insight into Z-drug abuse and dependence: an examination of reports to the European medicines agency database of suspected adverse drug reactions. Int J Neuropsychopharmacol 2019; 22(4): 270-7.
[http://dx.doi.org/10.1093/ijnp/pyz007] [PMID: 30722037]
[37]
Pollmann AS, Murphy AL, Bergman JC, Gardner DM. Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 2015; 16(1): 19.
[http://dx.doi.org/10.1186/s40360-015-0019-8] [PMID: 26141716]
[38]
Alghamdi B, Zrari M, Elahi A, et al. Substance abuse and its psychiatric effect on adolescence. Int J Community Med Public Health 2018; 5(7): 2642.
[http://dx.doi.org/10.18203/2394-6040.ijcmph20182450]
[39]
Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172(13): 1703-11.
[http://dx.doi.org/10.1503/cmaj.1041064] [PMID: 15967975]
[40]
Foley M, Breindahl T, Hindersson P, Deluca P, Kimergård A. Misuse of ‘over-the-counter’ codeine analgesics: does formulation play a role? Public Health 2016; 130: 95-6.
[http://dx.doi.org/10.1016/j.puhe.2015.10.006] [PMID: 26612458]
[41]
Kacha-Ochana A, Jones CM, Green JL, et al. Characteristics of adults aged ≥18 years evaluated for substance use and treatment planning — United States, 2019. MMWR Morb Mortal Wkly Rep 2022; 71(23): 749-56.
[http://dx.doi.org/10.15585/mmwr.mm7123a1] [PMID: 35679167]
[42]
Caleb O, Moses O, Onah D. Peer pressure, alcohol use and drugs abuse on anti-social behaviour among youths in makurdi metropolis, Benue State. J Couns Fam Ther 2019; 1(2): 1-8.
[43]
Ahern E, Kinsella S, Semkovska M. Clinical efficacy and economic evaluation of online cognitive behavioral therapy for major depressive disorder: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 2018; 18(1): 25-41.
[http://dx.doi.org/10.1080/14737167.2018.1407245] [PMID: 29145746]
[44]
Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996; 153(3): 311-20.
[http://dx.doi.org/10.1176/ajp.153.3.311] [PMID: 8610817]
[45]
(a) Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem 2014; 60(1): 53-9.
[http://dx.doi.org/10.1373/clinchem.2013.204446] [PMID: 24281779];
(b) Olson MT, Breaud A, Harlan R, et al. Alternative calibration strategies for the clinical laboratory: application to nortriptyline therapeutic drug monitoring. Clin Chem 2013; 59(6): 920-7.
[http://dx.doi.org/10.1373/clinchem.2012.194639] [PMID: 23426427]
[46]
Taylor D, Lenox-Smith A, Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther Adv Psychopharmacol 2013; 3(3): 151-61.
[http://dx.doi.org/10.1177/2045125312472890] [PMID: 24167687]
[47]
Evans EA, Sullivan MA. Abuse and misuse of antidepressants. Subst Abuse Rehabil 2014; 5: 107-20.
[PMID: 25187753]
[48]
Linder MW, Keck PE Jr. Standards of laboratory practice: antidepressant drug monitoring. Clin Chem 1998; 44(5): 1073-84.
[PMID: 9590392]
[49]
Vejar-Vivar C, García-Valverde MT, Mardones C, Lucena R, Cárdenas S. Polydopamine coated hypodermic needles as a microextraction device for the determination of tricyclic antidepressants in oral fluid by direct infusion MS/MS. RSC Advances 2021; 11(37): 22683-90.
[http://dx.doi.org/10.1039/D1RA02721B] [PMID: 35480419]
[50]
(a) Riahi-Zanjani B, Balali-Mood M, Es’haghi Z, Asoodeh A, Ghorani-Azam A. Molecular modeling and experimental study of a new peptide-based microextraction fiber for preconcentrating morphine in urine samples. J Mol Model 2019; 25(3): 54.
[http://dx.doi.org/10.1007/s00894-019-3925-7] [PMID: 30734871];
(b) Riahi-Zanjani B, Balali-Mood M, Es’haghi Z, Asoodeh A, Ghorani-Azam A. Preconcentration of morphine in urine sample using a green and solvent-free microextraction method. Green Processing and Synthesis 2019; 8(1): 542-50.
[http://dx.doi.org/10.1515/gps-2019-0023]
[51]
Mina A. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty. J Pharmacol Toxicol Methods 2020; 101: 106649.
[http://dx.doi.org/10.1016/j.vascn.2019.106649] [PMID: 31730939]
[52]
Tamama K. Advances in drugs of abuse testing. Clin Chim Acta 2021; 514: 40-7.
[http://dx.doi.org/10.1016/j.cca.2020.12.010] [PMID: 33333045]
[53]
(a) Riahi-Zanjani B. False positive and false negative results in urine drug screening tests: tampering methods and specimen integrity tests. Pharmacologyonline 2014; 1(1): 102-8.;
(b) Finn N, Wolf J, Louie J, Su B. High concentrations of dextromethorphan result in false-positive in opiate immunoassay test. Clin Chim Acta 2015; 448(448): 247.
[http://dx.doi.org/10.1016/j.cca.2015.07.015] [PMID: 26192219]
[54]
Bertholf RL, Johannsen LM, Reisfield GM. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results. J Anal Toxicol 2015; 39(1): 24-8.
[http://dx.doi.org/10.1093/jat/bku109] [PMID: 25288720]
[55]
Smith ML, Nichols DC, Underwood P, et al. Methamphetamine and amphetamine isomer concentrations in human urine following controlled Vicks VapoInhaler administration. J Anal Toxicol 2014; 38(8): 524-7.
[http://dx.doi.org/10.1093/jat/bku077] [PMID: 25217541]
[56]
Nixon AL, Long WH, Puopolo PR, Flood JG. Bupropion metabolites produce false-positive urine amphetamine results. Clin Chem 1995; 41(6): 955-6.
[http://dx.doi.org/10.1093/clinchem/41.6.955] [PMID: 7768026]
[57]
Fucci N. False positive results for amphetamine in urine of a patient with diabetes mellitus. Forensic Sci Int 2012; 223(1-3): e60-0.
[http://dx.doi.org/10.1016/j.forsciint.2012.08.010] [PMID: 23026178]
[58]
Kronstrand R, Andersson MC, Ahlner J, Larson G. Incorporation of selegiline metabolites into hair after oral selegiline intake. J Anal Toxicol 2001; 25(7): 594-601.
[http://dx.doi.org/10.1093/jat/25.7.594] [PMID: 11599606]
[59]
Moeller KE, Lee KC, Kissack JC. Urine drug screening: practical guide for cliniciansMayo Clin Proc 2008; 83(1): 66-76.
[http://dx.doi.org/10.4065/83.1.66]
[60]
Pettersson Bergstrand M, Helander A, Hansson T, Beck O. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays. Drug Test Anal 2017; 9(4): 640-5.
[http://dx.doi.org/10.1002/dta.2003] [PMID: 27366870]
[61]
Tonon MA, Bonato PS. Methods for the analysis of nonbenzodiazepine hypnotic drugs in biological matrices. Bioanalysis 2012; 4(3): 291-304.
[http://dx.doi.org/10.4155/bio.11.313] [PMID: 22303833]
[62]
Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet 2004; 43(4): 227-38.
[http://dx.doi.org/10.2165/00003088-200443040-00002] [PMID: 15005637]
[63]
Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol 2013; 9(2): 163-71.
[http://dx.doi.org/10.1007/s13181-013-0294-y] [PMID: 23456542]
[64]
Fitzgerald RL, Rexin DA, Herold DA. Detecting benzodiazepines: immunoassays compared with negative chemical ionization gas chromatography/mass spectrometry. Clin Chem 1994; 40(3): 373-80.
[http://dx.doi.org/10.1093/clinchem/40.3.373] [PMID: 8131270]
[65]
Proença P, Monteiro C, Mustra C, Claro A, Franco J, Corte-Real F. Identification and quantification of antipsychotics in blood samples by LC–MS-MS: Case reports and data from three years of routine analysis. J Anal Toxicol 2020; 44(8): 915-22.
[http://dx.doi.org/10.1093/jat/bkaa100] [PMID: 32780823]
[66]
Kale N. Urine drug tests: ordering and interpreting results. Am Fam Physician 2019; 99(1): 33-9.
[PMID: 30600984]
[67]
Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician 2010; 81(5): 635-40.
[PMID: 20187600]
[68]
Liu CH, Wang HY, Shen SH, Chiu YW. False positive ketamine urine immunoassay screen result induced by quetiapine: A case report. J Formos Med Assoc 2017; 116(9): 720-2.
[http://dx.doi.org/10.1016/j.jfma.2017.04.008] [PMID: 28495417]
[69]
Ritter D, Cortese CM, Edwards LC, Barr JL, Chung HD, Long C. Interference with testing for lysergic acid diethylamide. Clin Chem 1997; 43(4): 635-7.
[http://dx.doi.org/10.1093/clinchem/43.4.635] [PMID: 9105265]
[70]
Jarvis M, Williams J, Hurford M, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med 2017; 11(3): 163-73.
[http://dx.doi.org/10.1097/ADM.0000000000000323] [PMID: 28557958]
[71]
Leickly E, McDonell MG, Vilardaga R, et al. High levels of agreement between clinic-based ethyl glucuronide (EtG) immunoassays and laboratory-based mass spectrometry. Am J Drug Alcohol Abuse 2015; 41(3): 246-50.
[http://dx.doi.org/10.3109/00952990.2015.1011743] [PMID: 25695340]
[72]
Reisfield GM, Goldberger BA, Crews BO, et al. Ethyl glucuronide, ethyl sulfate, and ethanol in urine after sustained exposure to an ethanol-based hand sanitizer. J Anal Toxicol 2011; 35(2): 85-91.
[http://dx.doi.org/10.1093/anatox/35.2.85] [PMID: 21396227]
[73]
Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40(1): 581-616.
[http://dx.doi.org/10.1146/annurev.pharmtox.40.1.581] [PMID: 10836148]
[74]
Weintraub D, Linder MW. Amphetamine positive toxicology screen secondary to bupropion. Depress Anxiety 2000; 12(1): 53-4.
[http://dx.doi.org/10.1002/1520-6394(2000)12:1<53::AID-DA8>3.0.CO;2-4] [PMID: 10999247]
[75]
Reidy L, Walls HC, Steele BW. Crossreactivity of bupropion metabolite with enzyme-linked immunosorbent assays designed to detect amphetamine in urine. Ther Drug Monit 2011; 33(3): 366-8.
[http://dx.doi.org/10.1097/FTD.0b013e3182126d08] [PMID: 21436763]
[76]
Baron JM, Griggs DA, Nixon AL, Long WH, Flood JG. The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results. J Anal Toxicol 2011; 35(6): 364-8.
[http://dx.doi.org/10.1093/anatox/35.6.364] [PMID: 21740694]
[77]
Gear JL. False-positive toxicology screens. J Am Acad Child Adolesc Psychiatry 1996; 35(12): 1571-2.
[http://dx.doi.org/10.1097/00004583-199612000-00005] [PMID: 8973060]
[78]
Bond GR, Steele PE, Uges DRA. Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine. J Toxicol Clin Toxicol 2003; 41(7): 999-1002.
[http://dx.doi.org/10.1081/CLT-120026525] [PMID: 14705849]
[79]
Farley T M, Anderson E N, Feller J N. False-positive phencyclidine (PCP) on urine drug screen attributed to desvenlafaxine (Pristiq) use. Case Rep 2017; 2017: bcr-2017-222106.
[80]
Manousi N, Samanidou VF. Recent advances in the HPLC analysis of tricyclic antidepressants in bio-samples. Mini Rev Med Chem 2020; 20(1): 24-38.
[http://dx.doi.org/10.2174/1389557519666190617150518] [PMID: 31288718]
[81]
de Castro A, Concheiro M, Quintela O, Cruz A, López-Rivadulla M. LC–MS/MS method for the determination of nine antidepressants and some of their main metabolites in oral fluid and plasma. J Pharm Biomed Anal 2008; 48(1): 183-93.
[http://dx.doi.org/10.1016/j.jpba.2008.05.024] [PMID: 18602787]
[82]
(a) Chathanchirayil SJ. False positive urine drug screening for tricyclic antidepressants in patients taking quetiapine. Aust N Z J Psychiatry 2011; 45(9): 792-2.
[http://dx.doi.org/10.3109/00048674.2011.580451] [PMID: 21554196];
(b) Hendrickson RG, Morocco AP. Quetiapine cross-reactivity among three tricyclic antidepressant immunoassays. J Toxicol Clin Toxicol 2003; 41(2): 105-8.
[http://dx.doi.org/10.1081/CLT-120019122] [PMID: 12733845]
[83]
Dasgupta A, Wells A, Datta P. False-positive serum tricyclic antidepressant concentrations using fluorescence polarization immunoassay due to the presence of hydroxyzine and cetirizine. Ther Drug Monit 2006; 28(5): 662-7.
[PMID: 17038882]
[84]
Saidinejad M, Law T, Ewald MB. Interference by carbamazepine and oxcarbazepine with serum- and urine-screening assays for tricyclic antidepressants. Pediatrics 2007; 120(3): e504-9.
[http://dx.doi.org/10.1542/peds.2006-2199] [PMID: 17766494]
[85]
Hennion MC, Barcelo D. Strengths and limitations of immunoassays for effective and efficient use for pesticide analysis in water samples: A review. Anal Chim Acta 1998; 362(1): 3-34.
[http://dx.doi.org/10.1016/S0003-2670(97)00608-9]
[86]
Bertol E, Vaiano F, Borsotti M, Quercioli M, Mari F. Comparison of immunoassay screening tests and LC-MS-MS for urine detection of benzodiazepines and their metabolites: results of a national proficiency test. J Anal Toxicol 2013; 37(9): 659-64.
[http://dx.doi.org/10.1093/jat/bkt063] [PMID: 23943436]
[87]
Dasgupta A, Saldana S, Kinnaman G, Smith M, Johansen K. Analytical performance evaluation of EMIT II monoclonal amphetamine/methamphetamine assay: more specificity than EMIT d.a.u. monoclonal amphetamine/methamphetamine assay. Clin Chem 1993; 39(1): 104-8.
[http://dx.doi.org/10.1093/clinchem/39.1.104] [PMID: 8419030]
[88]
Matriciani B, Huppertz B, Keller R, Weiskirchen R. False-negative results in the immunoassay analysis of drugs of abuse: can adulterants be detected by sample check test? Ann Clin Biochem 2018; 55(3): 348-54.
[http://dx.doi.org/10.1177/0004563217725089] [PMID: 28728424]
[89]
Petrie M, Lynch KL, Ekins S, et al. Cross-reactivity studies and predictive modeling of “Bath Salts” and other amphetamine-type stimulants with amphetamine screening immunoassays. Clin Toxicol (Phila) 2013; 51(2): 83-91.
[http://dx.doi.org/10.3109/15563650.2013.768344] [PMID: 23387345]
[90]
Reisfield GM, Goldberger BA, Bertholf RL. ‘False-positive’ and ‘false-negative’ test results in clinical urine drug testing. Bioanalysis 2009; 1(5): 937-52.
[http://dx.doi.org/10.4155/bio.09.81] [PMID: 21083064]
[91]
Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci 2007; 37(4): 301-14.
[PMID: 18000286]
[92]
Silva RS, Domingueti CP, Tinoco MS, et al. Interference of medicines in laboratory exams. J Bras Patol Med Lab 2021; 57.

Rights & Permissions Print Cite
Article Metrics
16
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy